Hester Biosciences Ltd

Hester Biosciences Ltd maintains a relatively balanced capital structure, with a debt-to-equity ratio of 0.84, indicating moderate leverage. The company's liquidity position is characterized as medium, with a current ratio of 2.03, suggesting it can cover its short-term obligations but with limited excess capacity. However, the firm's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.

In terms of profitability, the company's return on equity (ROE) is 1.7%, and its return on assets (ROA) is 0.75%, both of which are below the typical thresholds for strong performance in the pharmaceutical industry. These figures suggest that the company is not generating significant returns relative to its equity and asset base, which may indicate inefficiencies or competitive pressures.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification beyond India. This concentration increases exposure to local market risks, including regulatory changes and currency fluctuations. The lack of segmental or geographic diversification could limit the company's ability to mitigate regional downturns.

Looking at the growth trajectory, the company's revenue has shown a modest increase in recent periods, but the outlook for the current and next fiscal years remains uncertain. The absence of clear growth drivers or expansion plans in the disclosed data suggests that the company may be operating in a stable but not rapidly growing market.

The risk assessment highlights a medium liquidity risk, primarily due to the negative net cash position after accounting for total debt. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. However, the company's capital structure and financial leverage could be sensitive to changes in interest rates or credit conditions.

Recent events, including filings and transcripts, do not indicate any major strategic shifts or significant operational changes. The company appears to be maintaining its current business model without major new initiatives or product launches disclosed in the available data.

Free cash flow surged 178.4% year-over-year to INR 198.7 million, demonstrating significant improvement in cash generation.

Revenue grew at a 9.8% compound annual growth rate over four years, showing consistent top-line expansion.

Cash conversion ratio of 9.72 is best-in-class compared to the cohort median of 0.95, highlighting strong cash management.

Debt-to-equity ratio of 0.84 places the company in the bottom quartile of peers, signaling high leverage risk.

The company faces high credit risk according to internal risk flags, potentially impacting borrowing costs and financial stability.

Revenue INR 3.05B, +14,4% YoY; Operating income +27,9% YoY.

• ▍Revenue INR 3.05B, +14,4% YoY
• ▍Operating income +27,9% YoY
• ▍Net income −29,1% YoY
• ▍Free cash flow +119,0% YoY
• ▍Net margin 6.2%

Revenue INR 2.66B, +13,2% YoY; Operating income −31,1% YoY.

• ▍Revenue INR 2.66B, +13,2% YoY
• ▍Operating income −31,1% YoY
• ▍Net income −32,3% YoY
• ▍Free cash flow +22,0% YoY
• ▍Net margin 10.0%

Revenue INR 2.35B, +9,7% YoY; Operating income −21,6% YoY.

• ▍Revenue INR 2.35B, +9,7% YoY
• ▍Operating income −21,6% YoY
• ▍Net income +14,2% YoY
• ▍Free cash flow −3 009,4% YoY
• ▍Net margin 16.7%

Revenue INR 2.14B; Operating income INR 553.5M.

• ▍Revenue INR 2.14B
• ▍Operating income INR 553.5M
• ▍Net margin 16.1%